GlassScriptPhysician profile
Matthew Mcintosh
NPI 1427187889
$2,381.71
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $227 · 2021: $306 · 2022: $505 · 2023: $303 · 2024: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.89 | 2019-2024 | |
| Genentech USA, INC. | $221.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $218.68 | 2019-2022 | |
| Abbvie INC. | $123.17 | 2023 | |
| Merck Sharp & Dohme LLC | $114.05 | 2019 | |
| Mylan Specialty L.P. | $114.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $106.15 | 2019-2023 | Trelegy Ellipta |
| Shionogi INC | $105.26 | 2024 | Fetroja |
| Amgen INC. | $89.64 | 2021-2023 | Tezspire |
| Gilead Sciences, INC. | $84.60 | 2022-2024 | Veklury |
| Novartis Pharmaceuticals Corporation | $79.80 | 2019 | |
| Grifols USA, LLC | $73.22 | 2020-2022 | |
| Boston Scientific Corporation | $61.87 | 2019 | |
| Genzyme Corporation | $59.62 | 2019-2022 | |
| Electromed, INC. | $37.47 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $34.35 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $29.63 | 2022 | |
| Mayne Pharma Commercial LLC | $27.87 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.49 | 2020 | |
| Jazz Pharmaceuticals INC. | $25.23 | 2022 | |
| Edwards Lifesciences Corporation | $24.98 | 2020 | |
| Sunovion Pharmaceuticals INC. | $24.96 | 2019 | |
| United Therapeutics Corporation | $21.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.10 | 2021 | |
| Astellas Pharma US INC | $16.26 | 2020 | |
| Circassia INC. | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.